Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Umbilical Cord Blood Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients meeting eligibility criteria for unrelated allogeneic stem cell transplantation may be considered for participation on this clinical trial if and only if they meet each of the following criteria:~* Patients must have one of the following diagnoses~* Relapsed or refractory hematologic malignancy, or~* High risk hematologic malignancy in first remission, or~* Refractory acquired marrow failure state, or~* Inherited disorder of metabolism or marrow failure state without alternative curative therapy.~* Patients must not have a 6/6 or 5/6 HLA-matched related donor.~* Patients must not have a HLA-A, -B and -DRB1 high resolution matched unrelated donor following registry search, or cannot (in the opinion of the treating physician) wait the median 3 months to receive a MUD unit.~* Patients must demonstrate an ability to understand and willingness to sign the informed consent document~Patients considered for myeloablative conditioning must satisfy the following additional criteria:~* Patients must be up to age 55 (inclusive)~* Patients must have serum direct bilirubin ≤ 2.0 mg/dl and transaminases ≤ 2x institution upper limit of normal~* Patients must have serum creatinine ≤ 2 mg/dl with creatinine clearance ≥ 60 ml/min (either calculated or measured).~* Patients must have MUGA scan or echocardiogram normal for the institution, but not less than 45% left ventricular ejection fraction and no clinical evidence of cardiac dysfunction.~* Patients must have an ECOG performance status of 0 or 1 (see Appendix C).~* Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 \> 50% of predicted.~Patients considered for reduced-intensity conditioning must satisfy the following additional criteria:~* Patients must not be candidates for myeloablative conditioning due to any one of the following: Prior myeloablative stem cell transplantation, Age \> 50, Co morbid illness~* In opinion of treating physician, unable to comply with or withstand rigors of myeloablative conditioning~* Patients with leukemia must have circulating and bone marrow blast counts \< 5%, all other patients must have chemotherapy responsive disease~* Patients must be between the ages of 18 and 70 (inclusive)~* Patients must have serum direct bilirubin ≤ 2.0 mg/dL and transaminases ≤ 3x institution upper limit of normal~* Patients must have creatinine clearance ≥ 30 ml/min (either calculated or measured).~* Patients must have MUGA scan or echocardiogram documenting left ventricular ejection fraction of no less than 35% and no clinical evidence of cardiac dysfunction.~Patients must have an ECOG performance status of 0 or 1 (see Appendix C).~Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 ≥ 40% of predicted.~Exclusion Criteria:~Patients are ineligible for participation on this trial if they meet any of the following criteria:~* Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, uncontrolled hypertension or congestive heart failure are ineligible.~* Patients with unstable angina are not eligible.~* Pregnant or lactating women are ineligible.~* Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.~* Patients with uncontrolled infection are ineligible.~* Patients who are HIV positive or have evidence of chronic viral hepatitis are ineligible.~* Patients unable to comply with requirements for compliance with therapeutic plan and/or scheduled evaluations

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Myeloablative conditioning (Type: EXPERIMENTAL): Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
- Reduced intensity conditioning (Type: EXPERIMENTAL): Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues